High-throughput functional analysis of CFTR and other apically localized channels in iPSC derived intestinal organoids
Sunny XiaiD, Zoltán BozókyiD, Onofrio LaselvaiD, Michelle Di PaolaiD, Saumel AhmadiiD, Jia Xin Jiang, Amy L. Pitstick, Chong JiangiD, Daniela RotiniD, Christopher N. MayhewiD, Nicola L. JonesiD, Christine E. BeariD
Abstract
Induced Pluripotent Stem Cells (iPSCs) can be differentiated into epithelial organoids that recapitulate the relevant context for CFTR and enable testing of therapies targeting Cystic Fibrosis (CF)-causing mutant proteins. However, to date, CF-iPSC-derived organoids have only been used to study pharmacological modulation of mutant CFTR channel activity and not the activity of other disease relevant membrane protein constituents. In the current work, we describe a high-throughput, fluorescence-based assay of CFTR channel activity in iPSC-derived intestinal organoids and describe how this method can be adapted to study other apical membrane proteins. In these proof-of-concept studies, we show how this fluorescence-based assay of apical membrane potential can be employed to study CFTR and ENaC channels and an electrogenic acid transporter in the same iPSC-derived intestinal tissue. This multiparameter phenotypic platform promises to expand CF therapy discovery to include strategies to target multiple determinants of epithelial fluid transport.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 24
- FWCI
- 2.91
- Field percentile
- top 8%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A multimodal iPSC platform for cystic fibrosis drug testing
Andrew C. Berical, Rhianna E. Lee, … Finn J Hawkins·Nature CommunicationsPeer-reviewed·Jul 29, 2022
- A new platform for high-throughput therapy testing on iPSC-derived, immature airway from Cystic Fibrosis Patients
Jia Xin Jiang, Leigh Wellhauser, … Christine E. Bear·Stem Cell ReportsPeer-reviewed·Oct 22, 2021
- Benchmarking organ-specific responses to therapies in tissues differentiated from Cystic Fibrosis patient derived iPSCs
Abdelkader Daoud, Sunny Xia, … Christine E. Bear·Stem Cell ResearchPeer-reviewed·Jan 6, 2025
- Fluorescence assay for simultaneous quantification of CFTR ion-channel function and plasma membrane proximity
S. Prins, E. Langron, … P. Vergani·bioRxiv·May 5, 2020
- Drug repurposing for Cystic Fibrosis: identification of drugs that induce CFTR-independent fluid secretion in nasal organoids
L. W. Rodenburg, L. Delpiano, … G. D. Amatngalim·bioRxiv·Sep 23, 2022
- FDA-Approved Drug Screening in Patient-Derived Organoids Demonstrates Potential of Drug Repurposing for Rare Cystic Fibrosis Genotypes
Eyleen de Poel, Sacha Spelier, … Jeffrey Matthijn Beekman·Journal of Cystic FibrosisPeer-reviewed·May 1, 2023